This article was originally published in The Tan Sheet
Firms "have substantially narrowed the remaining open matters with both" FTC and European regulatory authorities "to a relatively small number of issues," Pfizer and Pharmacia report Dec. 5. Companies are "confident" transaction will close in first quarter 2003; original target had been year end (1"The Tan Sheet" July 22, 2002, p. 8). Pfizer shareholders voted to approve the deal Dec. 6...
You may also be interested in...
Pfizer's acquisition of Pharmacia likely will draw antitrust regulatory scrutiny to one of the combined firm's smallest product lines - OTC motion sickness tablets
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients